Sensei Biotherapeutics, Inc. (NASDAQ:FTH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Sensei Biotherapeutics, Inc. (NASDAQ:FTH) have earned an average recommendation of “Moderate Buy” from the twelve analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $54.90.

Several brokerages have recently issued reports on FTH. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 price target on shares of Sensei Biotherapeutics in a research report on Tuesday. Leerink Partners started coverage on Sensei Biotherapeutics in a research report on Monday, April 20th. They set an “outperform” rating and a $50.00 price objective for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research note on Thursday, June 4th. Oppenheimer initiated coverage on Sensei Biotherapeutics in a report on Tuesday, July 28th. They issued an “outperform” rating and a $60.00 target price on the stock. Finally, Raymond James Financial started coverage on Sensei Biotherapeutics in a research report on Friday, July 31st. They issued an “outperform” rating and a $56.00 price target on the stock.

Insider Transactions at Sensei Biotherapeutics

In related news, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was purchased at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the purchase, the chief executive officer directly owned 764,234 shares in the company, valued at $15,101,263.84. This trade represents a 0.37% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder James Peyer sold 25,000 shares of the stock in a transaction on Monday, June 1st. The shares were sold at an average price of $20.02, for a total transaction of $500,500.00. Following the completion of the sale, the insider directly owned 130,142 shares of the company’s stock, valued at approximately $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have purchased 49,494 shares of company stock worth $1,188,822. Insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Renaissance Technologies LLC lifted its stake in shares of Sensei Biotherapeutics by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after buying an additional 1,100 shares during the period. Bank of America Corp DE increased its stake in Sensei Biotherapeutics by 10,692.5% during the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after acquiring an additional 32,719 shares during the period. Stempoint Capital LP bought a new position in Sensei Biotherapeutics during the first quarter valued at about $4,188,000. Finally, Vivo Capital LLC bought a new position in Sensei Biotherapeutics during the first quarter valued at about $22,758,000. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Trading Down 2.1%

NASDAQ FTH opened at $29.38 on Thursday. The business’s fifty day moving average price is $26.47. The company has a market cap of $39.43 million, a P/E ratio of -0.21 and a beta of -0.25. Sensei Biotherapeutics has a 1 year low of $7.21 and a 1 year high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. As a group, sell-side analysts anticipate that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.